NICE amends ranibizumab guidance

NICE has overturned its original decision to reject the VEGF-targeting antibody ranibizumab (Lucentis) in the treatment of diabetic macular oedema.

Ranibizumab is also recommended by NICE for the treatment of wet age-related macular degeneration | SCIENCE PHOTO LIBRARY
Ranibizumab is also recommended by NICE for the treatment of wet age-related macular degeneration | SCIENCE PHOTO LIBRARY

In a review of its 2011 guidance, NICE has ruled that ranibizumab can be considered for the treatment of visual impairment due to diabetic macular oedema, providing the eye has a central retinal thickness of 400 micrometers or more at the start of treatment.

The NICE recommendations are made on the proviso that the manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012).

In addition to the revised patient access scheme, the decision was based on an updated clinical analysis of ranibizumab submitted by the manufacturer.

NICE guidance on ranibizumab in diabetic macular oedema

Follow MIMS on Twitter


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.